Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Schedule of Segment Information

The tables below present segment information reconciled to total Company loss from operations, with segment operating loss including gross profit less direct research and development expenses and direct selling, general and administrative expenses to the extent specifically identified by segment:

	Three Months Ended March 31, 2022
	(in thousands)
	Water Filtration			Pathogen Detection			Renal Products			Nephros, Inc. Consolidated
Total net revenues	$	2,159		$	28		$	-		$	2,187
Gross margin (loss)		1,053			(28	)		-			1,025
Research and development expenses		255			206			117			578
Depreciation and amortization expense		51			1			-			52
Selling, general and administrative expenses		2,150			171			27			2,348
Total operating expenses		2,456			378			144			2,978
Loss from operations	$	(1,403	)	$	(406	)	$	(144	)	$	(1,953	)

	Three Months Ended March 31, 2021
	(in thousands)
	Water Filtration			Pathogen Detection			Renal Products			Nephros, Inc. Consolidated
Total net revenues	$	2,736		$	-		$	-		$	2,736
Gross margin		1,587			-			-			1,587
Research and development expenses		294			119			143			556
Depreciation and amortization expense		50			-			-			50
Selling, general and administrative expenses		1,876			101			22			1,999
Total operating expenses		2,220			220			165			2,605
Loss from operations	$	(633	)	$	(220	)	$	(165	)	$	(1,018	)